Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2022 08:00 ET | Source: Cerevance

Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology

Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results...
November 15, 2022 08:00 ET | Source: Cerevance

Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference

– Data demonstrated C101248 is a promising inhibitor of THIK-1, an emerging target in Alzheimer’s disease –– THIK-1 was identified using Cerevance’s proprietary NETSseq platform – BOSTON, Nov. 15,...
November 07, 2022 08:00 ET | Source: Cerevance

Cerevance to Present at the Society for Neuroscience (SFN) 2022

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster...
October 03, 2022 10:17 ET | Source: Cerevance

Cerevance Appoints Ottavio V. Vitolo, M.D., as Chief Medical Officer

BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the...
August 09, 2022 08:00 ET | Source: Cerevance

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Cerevance to concurrently out-license one discovery-stage program BOSTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company...
June 16, 2022 10:17 ET | Source: Cerevance

Cerevance to Present During the 5th Annual LSX World Congress USA

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Carrie...
June 08, 2022 10:17 ET | Source: Cerevance

Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention

BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig...
April 19, 2022 10:17 ET | Source: Cerevance

Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

Craig Thompson Appointed Chief Executive Officer Founder Brad Margus Assumes Role of Executive Chairman of the Board BOSTON, April 19, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage...
March 31, 2022 10:17 ET | Source: Cerevance

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

BOSTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the...
January 25, 2022 10:17 ET | Source: Cerevance

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the dosing of the...